Per cent of dermatologists (DE) (n=167) and rheumatologists (RH) (n=173) in Germany (GER) (nDE=52, nRH=64), the UK (nDE=51, nRH=54) and the USA (nDE=64, nRH=55) who rated their knowledge (K) and skills (S) at suboptimal levels (none, basic, intermediate) compared with what is expected in their professional role
| GER % (n) | UK % (n) | USA % (n) | Total % (n) | P value | |||
| 1 | K: The impact of PsO/axSpA, PsA and RA on women’s reproductive health | DE | 27.5 (14) | 52.0 (26) | 59.4 (38) | 47.3 (78) | 0.002* |
| 2 | RH | 35.9 (23) | 44.4 (24) | 31.5 (17) | 37.2 (64) | 0.366 | |
| 3 | K: Safety data of biologic injectables for female patients with moderate to severe PsO/axSpA, PsA and RA who are pregnant | DE | 42.3 (22) | 70.6 (36) | 57.8 (37) | 56.9 (95) | 0.015* |
| 4 | RH | 50.8 (32) | 51.9 (28) | 41.8 (23) | 48.3 (83) | 0.508 | |
| 5 | K: Safety data of biologic injectables for female patients with moderate to severe PsO/axSpA, PsA and RA who are breast feeding | DE | 42.3 (22) | 68.6 (35) | 56.3 (36) | 55.7 (93) | 0.027* |
| 6 | RH | 52.4 (33) | 55.6 (30) | 49.1 (27) | 52.3 (90) | 0.796 | |
| 7 | S: Discussing contraceptive methods with patients | DE | 38.5 (20) | 60.0 (30) | 52.4 (33) | 56.9 (189) | 0.003* |
| RH | 58.1 (36) | 78.8 (41) | 54.7 (29) | ||||
| 8 | S: Closely monitoring changes in pregnancy status or childbearing aspiration | DE | 56.0 (28) | 76.0 (38) | 67.2 (43) | 63.6 (211) | 0.121 |
| RH | 65.1 (41) | 65.4 (34) | 50.9 (27) | ||||
| 9 | S: Making appropriate treatment adjustments in the face of an unplanned pregnancy | DE | 56.9 (29) | 64.7 (33) | 53.1 (34) | 53.1 (179) | 0.183 |
| RH | 44.4 (28) | 58.5 (31) | 43.6 (24) | ||||
| 10 | K: Strategies for shared decision-making between physicians and patients | DE | 30.8 (16) | 30.6 (15) | 42.2 (27) | 35.5 (120) | 0.762 |
| RH | 34.4 (22) | 38.9 (21) | 34.5 (19) | ||||
| 11 | S: Assessing patient’s desired level of involvement in medical decisions that inevitably impact their health | DE | 32.7 (17) | 37.3 (27) | 37.5 (24) | 37.8 (128) | 0.720 |
| RH | 40.6 (26) | 50.9 (27) | 27.3 (15) | ||||
| 12 | S: Adapting to patient’s health literacy level when explaining treatment options | DE | 34.6 (18) | 37.3 (19) | 48.4 (31) | 35.3 (120) | 0.009* |
| RH | 28.1 (18) | 44.4 (24) | 18.2 (10) | ||||
| 13 | S: Identifying patient’s motive for a certain treatment preference | DE | 36.5 (19) | 33.3 (17) | 43.8 (28) | 38.8 (131) | 0.446 |
| RH | 36.5 (23) | 49.1 (17) | 32.7 (18) | ||||
| 14 | S: Helping patients set aspirational and realistic treatment targets with patients and their healthcare team | DE | 45.1 (23) | 48.0 (24) | 45.3 (29) | 39.6 (133) | 0.060 |
| RH | 36.5 (23) | 41.5 (22) | 21.8 (12) | ||||
| 15 | K: Patient education aids relevant to women of reproductive age with PsO/axSpA, PsA and RA | DE | 38.5 (20) | 62.7 (32) | 48.4 (31) | 49.7 (83) | 0.046* |
| 16 | RH | 31.7 (20) | 53.7 (29) | 41.8 (23) | 41.9 (72) | 0.056 | |
| 17 | S: Involving general practitioners in the monitoring and co-management of patients | DE | 38.0 (19) | 44.9 (22) | 60.9 (39) | 39.8 (133) | 0.001 |
| RH | 26.6 (17) | 28.3 (15) | 38.9 (21) | ||||
| 18 | S: Selecting compatible treatments with obstetrician and/or gynaecologists for women of reproductive age with a diagnosis of PsO/axSpA, PsA or RA | DE | 40.4 (21) | 58.8 (30) | 43.8 (28) | 47.3 (79) | 0.133 |
| 19 | RH | 35.9 (23) | 50.9 (27) | 38.2 (21) | 41.3 (71) | 0.222 | |
Compared proportions (frequencies) of DE and RH in GER, the UK and the USA who reported a suboptimal level of K or S, meaning they selected either 1 (no knowledge/skill), 2 (basic) or 3 (intermediate) over 4 (advanced) or 5 (expert). Where specification was necessary, DE were asked about psoriasis (PsO) and RH about axial spondyloarthritis (axSpA), psoriatic arthritis (PsA) and rheumatoid arthritis (RA). Therefore, depending on the item, Χ2 tests with 2 or 5 df were performed. Participants who selected ‘not relevant to my current role’ were excluded from analysis.
*Significant difference (p<0.05).